Molecular biology of gastric carcinoma: From laboratory to bedside

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue 12, 1999, Pages 1150-1160

  Chan, Annie On On ^a   Mc Luk, John ^a   Hui, Wai Mo ^a   Lam, Shiu Kum ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Gastric carcinoma; Helicobacter pylori; Molecular biology

Indexed keywords

NERVE CELL ADHESION MOLECULE; TELOMERASE;

CANCER GROWTH; CARCINOGENESIS; COLORECTAL CANCER; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STOMACH CARCINOMA;

EID: 0033403136     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.02000.x     Document Type: Review

References (117)

1. 1 Aird I, Bentall H, Roberts JF. Relationship between cancer of stomach and the ABO blood groups. BMJ. 1953; 1: 799-801.
2. 2 Guilford P, Hopkins J, Harraway J et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-5.
3. 3 Bartsch H, O'Neill I, Hermann R. The Relevance of N-nitroso Compounds to Human Cancer. Exposures and Mechanisms, IARC Scientific Publications No 84. Lyon: International Agency for Research on Cancer, 1987.
4. 4 Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 1991; 325: 1127-31.
5. 5 Correa P, Haenszel W, Cuello C, Arder M, Tannenbaum SR. A model for gastric cancer epidemiology. Lancet 1975; 2: 58-60.
6. 6 Correa P. The gastric precancerous process. Cancer Surv. 1983; 2: 437-50.
7. 7 Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988; 48: 3554-60.
8. 8 Forman D. Lessons from ongoing intervention studies. In: Hunt RH, Tytgat GNJ (eds). Helicobacter pylori: Basic Mechanisms to Clinical Care, 1998. Dordrecht: Kluwer Academic Publishers, 1998; 354-60.
9. 9 Moss SF, Calam J, Agarwal B, Wang S, Holt PG. Induction of gastric epithelial apoptosis by Helicobacter pylori. Gut 1996; 38: 498-501.
10. 10 Jones NL, Yeger H, Cutz E, Sherman PM. Helicobacter pylori induces apoptosis of gastric antral epithelial cells in vivo. Gastroenterology 1996; 110: A933.
11. 11 Bravo LE, Mannick EE, Zhang X-J, Ruiz B, Correa P, Miller MJS. H. pylori infection is associated with inducible nitric oxide synthase expression, nitrotyrosine and DNA damage. Gastroenterology 1995; 108: A63 (Abstract).
12. 12 Terres AM, Pajares JM, O'Toole D, Ahern S, Kelleher D. H. pylori infection is associated with downregulation of E-cadherin, a molecule involved in epithelial cell adhesion and proliferation control. J. Clin. Pathol. 1998; 51: 410-12.
13. 13 Kuniyasu H, Domen T, Hamamoto T et al. Expression of human telomerase RNA is an early event of stomach carcinogenesis. Jpn. J. Cancer Res. 1997; 88: 103-7.
14. 14 Lin ST, Wu MS, Shun CT. et al. Microsatellite instability in gastric carcinoma with special references to histopathology and cancer stages. Eur. J. Cancer 1995; 31A: 1879-82.
15. 15 Wu MS, Shun CT, Wang HP et al. Genetic alterations in gastric cancer: Relation to histological subtypes, tumour stage and Helicobacter pylori infection. Gastroenterology 1997; 112: 1457-65.
16. 16 Fearon ER, Vogolstein B. A genetic model for colorectal tumorogenesis. Cell 1990; 61: 759-67.
17. 17 Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. Acta Pathol. Microbiol. Scand. 1965; 64: 31-49.
18. 18 Strickler JG, Zheng J, Shu Q, Burgart U, Alberts SR, Shibata D. P53 mutations and microsatellite instability in sporadic gastric cancer: When guardians fall. Cancer Res. 1994; 54: 4750-5.
19. 19 Semba S, Yokozaki H, Yamamoto S, Yasui W, Tahara E. Microsatellite instability in precancerous lesions and adenocarcinomas of the stomach. Cancer 1996; 77: 1620-7.
20. 20 Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with aging. Nature 1990; 346: 866-8.
21. 21 Tahara E, Kuniyasu H, Yasui W, Yokozaki H. Gene alterations in intestinal metaplasia and gastric cancer. Eur. J. Gastroenterol. Hepalol. 1994; 6 (Suppl. 1): S97-101.
22. 22 Kihana T, Tsuda H, Hirota T et al. Point mutation of c-Ki-ras oncogene in gastric adenoma and adenocarcinoma with tubular differentiation. Jpn. J. Cancer Res. 1991; 82: 308-14.
23. 23 Tahara E, Yasui W, Taniyama K et al. Ha-ras oncogene product in human gastric carcinoma: Correlation with invasiveness, metastasis or prognosis. Jpn. J. Cancer Res. 1986; 77: 517-22.
24. 24 Yoshida K, Hamatani K, Koide H et al. Analysis of ras gene expression in stomach cancer by anti-ras p21 monoclonal antibodies. Cancer Detect. Prev. 1988; 12: 369-76.
25. 25 Czerniak B, Herz F, Gorczyca W, Koss LG. Expression of ras oncogene p21 protein in early gastric carcinomas and adjacent gastric epithelia. Cancer 1989; 64: 1467-73.
26. 26 Czerniak B, Herz F, Koss LG, Sclom J. Ras oncogene p21 as a tumour marker in the cytodiagnosis of gastric and colonic carcinomas. Cancer 1987; 60: 2432-6.
27. 27 Ohuchi N, Hand PH, Merio G et al. Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridisation. Cancer Res. 1987; 47: 1413-20.
28. 28 Tamura G, Maesawa C, Suzuki Y et al. Mutations of the APC gene occur during early stages of gastric adenoma development. Cancer Res. 1994; 54: 1149-51.
29. 29 Tohdo H, Yokozaki H, Haruma K, Kajiyama G, Tahara E. P53 gene mutations in gastric adenomas. Virchows Arch. B. Cell Pathol. 1993; 63: 191-5.
30. 30 Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD. P53 alterations in gastric precancerous lesions. Am. J. Pathol. 1994; 144: 511-17.
31. 31 Ochiai A, Yamauchi Y, Hirohashi S. P53 mutations in the non-neoplasric mucosa of the human stomach showing intestinal metaplasia. Int. J. Cancer 1996; 69: 28-33.
32. 32 Murakami T, Early cancer of the stomach. World J. Surg. 1979; 3: 685-92.
33. 33 Abe S, Ogawa Y, Nagasue N. Early gastric cancer: Results in a general hospital in Japan. World J. Surg. 1984; 8: 308-14.
34. 34 Hayashida T. End results of early gastric cancer collected from 22 institutions. Stomach Intestine 1969; 4: 1077.
35. 35 Gentsch H, Groitl H, Giedl J. Results of surgical treatment of early gastric cancer in 113 patients. World J. Surg. 1981; 5: 103-7.
36. 36 Oleagoitea J, Echevarria A, Santidrian J, Ulacia M, Hernandez-Calvo J. Early gastric cancer. Br. J. Surg. 1986; 73: 804-6.
37. 37 Kodama Y, Inokuchi K, Sejima K, Matsusaka T, Okamura T. Growth pattern and prognosis in early gastric carcinoma: Superficially spreading and penetrating growth types. Cancer 1983; 51: 320-6.
38. 38 Oiwa H, Maehara Y, Ohno S, Sakaguchi Y, Ichiyoshi Y, Sugimachi K. Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer 1995; 75 (Suppl.): 1454-9.
39. 39 Fonseca L, Yonemura Y, DeAretxabala X, Yamaguchi A, Miwa K, Miyazaki I. P53 detection as a prognostic factor in early gastric cancer. Oncology 1994; 51: 485-90.
40. 40 Fey MF, Hesketh C, Wainscoat JS, Gendler S, Thein SL. Clonal allele loss in gastrointestinal cancers. Br. J. Cancer 1989; 59: 750-4.
41. 41 Wada M, Yokota J, Mizoguchi H, Sugimura T, Terada M. Infrequent loss of chromosomal heterozygosity in human stomach cancer. Cancer Res. 1988; 48: 2988-92.
42. 42 Sano T, Tsujino T, Yoshida K et al. Frequent loss of heterozygosity on chromosomes 1q, 5q and 17p in human gastric carcinomas. Cancer Res, 1991;51:2926-31.
43. 43 Michelassi F, Errol F, Angriman I, Westbrook C. Chromosome 5 allele loss in human gastric, ampullary and pancreatic carcinomas. Ital. J. Surg. Sci. 1989; 19: 341-4.
44. 44 Motomura K, Nishisho I, Takai S et al. Loss of alleles at loci on chromosome 13 in human primary gastric cancers. Genomics 1988; 2: 180-4.
45. 45 Nakatsuru S, Yanagisawa A, Ichii S et al. Somatic mutation of the APC gene in gastric cancer: Frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma. Hum. Mol. Genet. 1992; 1: 559-63.
46. 46 Peifer M. Cancer, catenins, and cuticle pattern: A complex connection. Science 1993; 262: 1667-8.
47. 47 Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR. Association of the APC gene product with β-catenin. Science 1993; 262: 1731-4.
48. 48 Su LK, Vogelstein B, Kinzler KW. Association of the APC tumour suppressor protein with catenins. Science 1993; 262: 1734-7.
49. 49 Powell SM, Zilz N, Beazer-Barday Y et al. APC mutations occur early during colorectal tumourigenesis, Nature 1992; 359: 235-7.
50. 50 Uchino S, Tsuda H, Noguchi M et al. Frequent loss of heterozgosity at the DCC locus in gastric cancer. Cancer Res. 1992; 52: 3099-102.
51. 51 Yoshida Y, Itoh F, EndoT, Hinoda Y, Imai K, Decreased DCC mRNA expression in human gastric cancers is clinicopathologically significant. Int. J. Cancer 1998; 79: 634-9.
52. 52 Vogelstein B, Kinzler KW. P53 function and dysfunction. Cell 1992; 70: 523-6.
53. 53 Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
54. 54 Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S. P53 mutation in gastric cancer: A genetic model for carcinogenesis is common to gastric and colorectal cancer. Int. J. Cancer 1993; 54: 759-64.
55. 55 Kim JH, Takahashi T, Chiba I et al. Occurrence of p53 abnormalities in gastric carcinoma tumours and cell lines. J. Natl Cancer Inst. 1991; 83: 938-43.
56. 56 Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. P53 expression and prognosis in gastric carcinoma. Int. J. Cancer 1992; 50: 859-62.
57. 57 Brito MJ, Williams GT, Thompson H, Filipe MI. Expression of p53 in early (TI) gastric carcinoma and precancerous adjacent mucosa. Gut 1994; 35: 1697-700.
58. 58 Monig SP, Eidt S, Zirbes TK, Stippel D, Baldus SE, Pichlmaier H. P53 expression in gastric cancer. Dig. Dis. Sci. 1997; 42: 2465-7.
59. 59 Cooper GM. Cellular transforming genes. Science 1982; 217: 801-6.
60. 60 Land H, Parada LF, Weinberg RA. Cellular oncogenes and multistep carcinogenesis. Science 1983; 222: 771-8.
61. 61 Nanus DM, Kelsen DP, Mentle IR, Altorki N, Albino AP. Infrequent point mutations of ras oncogenes in gastric cancers. Gastroenterology 1990; 98: 955-60.
62. 62 Noguchi M, Hirohashi S, Shimosato Y et al. Histologic demonstration of antigens reactive with anti-p21 ras monoclonal antibody (RAP-5) in human stomach cancers. J. Natl Cancer Inst. 1986; 77: 379-85.
63. 63 Fujita K, Ohuchi N, Yao T et al. Frequent overexpression, but not activation by point mutation, of ras genes in primary human gastric cancers. Gastroenterology 1987; 93: 1339-45.
64. 64 Yamamoto T, Hattori T, Tahara E. Interaction between transforming growth factor alpha and c-Ha-ras p21 in progression of human gastric carcinoma. Pathol. Res. Pract. 1988; 183: 663-9.
65. 65 Ranzani GN, Pellegata NS, Previdere C et al. Heterogeneous proto-oncogene amplification correlates with tumour progression and presence of metastases in gastric cancer patients. Cancer Res. 1990; 50: 7811-14.
66. 66 Shibuya M, Yokota J, Ueyama Y. Amplification and expression of a cellular oncogene (c-myc) in human gastric adenocarcinoma cells. Mol. Cell Biol. 1985; 5: 414-18.
67. 67 Ciclitira PJ, Macartney JC, Evan G, Expression of c-myc in non-malignant and pre-malignant gastrointestinal disorders. J. Pathol. 1987; 151: 293-6.
68. 68 Spandidos DA, Karayiannis M, Yiagnisis M, Papadinitrion K, Field JK. Immunohistochemical analysis of the expression of the c-myc oncoprotein in human stomach cancers. Digestion 1991; 50: 127-34.
69. 69 Ninomiya J, Yonemura Y, Matsumoto H et al. Expression of c-myc gene product in gastric carcinoma. Oncology 1991; 48: 149-53.
70. 70 Moss SF, Arber N, Hibshoosh N et al. Cyclin D1 expression in gastric carcinogenesis. Gut 1996; 39 (Suppl. 2): A18-19.
71. 71 Akama Y, Yasui W, Yokozaki H et al. Frequent amplification of the cyclin E gene in human gastric carcinomas. Jpn.J. Cancer Res. 1995; 86: 617-21.
72. 72 Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem. Biophys. Res. Commun. 1992; 189: 227-32.
73. 73 Kuniyasu H, Yasui W, Yokozaki H, Kitadai Y, Tahara E. Aberrant expression of c-met mRNA in human gastric carcinomas. Int. J. Cancer 1993; 55: 72-5.
74. 74 Taniguchi T, Kitamura M, Iwasaki Y, Yamamoto Y, Igari A, Toi M. Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br. J. Cancer 1997; 75: 673-7.
75. 75 Tahara E. Molecular mechanism of stomach carcinogenesis. J. Cancer Res. Clin. Oncol. 1993; 119: 265-72.
76. 76 Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-6.
77. 77 Coussens L, Yang-Feng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-9.
78. ERBB2 expression and the gene amplification. Cancer Res. 1990; 50: 8002-9.
79. 79 Jain S, Filipe MI, Gullick WJ, Linehan J, Moris RW. C-erbB2 protooncogene expression and its relationship to survival in gastric carcinoma: An immunohistochemical study on archive material. Int. J. Cancer 1991; 48: 668-71.
80. 80 Yonemura Y, Ninomiya I, Yamaguchi A et al. Evaluation of immunoreactivity for erbB2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991; 51: 1034-8.
81. 81 Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y. Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993; 72: 2083-8.
82. 82 Tal M, Wetzler M, Josefberg Z et al. Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res. 1988; 48: 1517-20.
83. 83 Tahara E. Growth factors and oncogenes in human gastrointestinal carcinoma. J. Cancer Res. Clin. Oncol. 1990; 116: 121-31.
84. 84 Yonemura Y, Takemura H, Ninomiya I et al. Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer. Oncology 1992; 49: 157-61.
85. 85 Yasui W, Hata J, Yokozaki H, Nakatani H, Ochiai A, Tahara E. Interaction between EGF and its receptor in progression of human gastric carcinoma. Int. J. Cancer 1988; 41: 211-17.
86. 86 Tokunaga A, Onda M, Okuda T et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and 2-erbB-2 in human gastric cancer. Cancer 1995; 75: 1418-25.
87. 87 Kuniyasu H, Yoshida K, Yokozaki H et al. Expression of cripto, a novel gene of the epidermal growth factor family, in human gastrointestinal carcinomas. Jpn. J. Cancer Res. 1991; 82: 969-73.
88. 88 Ito M, Yasui W, Kyo E et al. Growth inhibition of transforming growth factor β on human gastric carcinoma cells: Receptor and postreceptor signaling. Cancer Res. 1992; 52: 295-300.
89. 89 Yanighara K, Tsurnuraya M. Transforming growth factor beta-1 induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res. 1992; 52: 4042-5.
90. 90 Chen RY, Ebner R, Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGFβ activities. Science 1993; 260: 1335-8.
91. 91 Naef M, Ishiwata T, Friess H, Buchler MW, Gold LI, Korc M. Over-expression of transforming growth factor β isoforms in human gastric carcinoma. Gastroenterology 1996; 110: A565 (Abstract).
92. 92 Ito M, Yasui W, Nakayama H, Yokozaki H, Ito H, Tahara E. Reduced level of transforming growth factor-β type I receptor in human gastric carcinomas. Jpn. J. Cancer Res. 1992; 83: 86-92.
93. 93 Park K, Kim SJ, Bang YJ et al. Genetic changes in the transforming growth factor beta type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-beta. Proc. Natl Acad. Sci. USA. 1994; 91: 8772-6.
94. 94 Oda T, Kanai Y, Oyama T et al. E-cadherin gene mutations in human gastric carcinoma cell lines. Proc. Natl Acad. Sci. USA 1994; 91: 1858-62.
95. 95 Yasui W, Kuniyasu H, Akama Y et al. Expression of E-cadherin, alpha and beta-catenins in human gastric carcinomas: Correlation with histology and tumour progression. Oncol. Rep. 1995; 2: 111-17.
96. 96 Shimoyama Y, Hirohashi S. Expression of E- and P-cadherin in gastric carcinomas. Cancer Res. 1991; 51: 2185-92.
97. 97 Mayer B, Jauch KW; Gunthert U et al. De-novo expression of CD44 and survival in gastric cancer. Lancet 1993; 342: 1019-22.
98. 98 Gabbert HE, Mueller W, Schneiders A et al. Prognostic value of E-cadherin expression in 413 gastric carcinomas. Int. J. Cancer 1996; 69: 184-9.
99. 99 Jackson DG, Buckley J, Bell JI. Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J. Biol. Chem. 1992; 267: 4732-9.
100. 100 Birch M, Mitchell S, Hart IR. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res. 1991; 51: 6660-7.
101. 101 Cooper DL, Dougherty G, Harn HJ et al. The complex CD44 transcriptional units; alternative splicing of three internal exons generates the epithelial form of CD44. Biochem. Biophys. Res. Commun. 1992; 182: 569-78.
102. 102 Yokozaki H, Ito R, Nakayama H, Kuniyasu H, Taniyama K, Tahara E. Expression of CD44 abnormal transcripts in human gastric carcinomas. Cancer Lett. 1994; 83: 229-34.
103. 103 Ayhan A, Yasui W, Yokozaki H, Kitadai Y, Tahara E. Reduced expression of nm23 protein is associated with advanced tumour stage and distant metastases in human colorectal carcinomas. Virchows Arch. B 1993; 63: 213-18.
104. 104 D'Errico A, Garbisa S, Liotta LA, Castronovo V, Stetler-Sterenson WG, Grigioni WF. Augmentation of type IV collagenase, laminin receptor, ki67 proliferative antigen associated with human colon, gastric and breast carcinoma progression. Mod. Pathol. 1991; 4: 239-46.
105. 105 Nekarda H, Schmitt M, Ulm K et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994; 54: 2900-7.
106. 106 Han HJ, Yanagisawa A, Kato Y, Park JG, Nakamura Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res. 1993; 53: 5087-9.
107. 107 Ranzani GN, Luinetti O, Padovan LS et al. P53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol. Biomarkers Prev. 1995; 4: 223-31.
108. 108 Tahara E. Molecular biology of gastric cancer. World J. Surg. 1995; 19: 484-90.
109. 109 Giardiello FM, Brensinger JD, Peter GM et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N. Engl. J. Med. 1997; 336: 823-7.
110. 110 Hermanek P, Wittekind C. News of TNM and its use for classification of gastric cancer. World J. Surg. 1995; 19: 491-5.
111. 111 Tahara E. Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer Suppl. 1995; 75: 1410-17.
112. 112 Jessup JM, Thomas P. Carcinoembryonic antigen: Function in metastasis by human colorectal carcinoma. Cancer Metatstasis Rev. 1989; 8: 263-80.
113. a as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer 1995; 75: 2051-6.
114. 114 Shimono R, Mori M, Akazawa K, Adchi Y, Sugimachi K. Immunohistochemical expression of carbohydrate antigen 19-9 in colorectal carcinoma. Am. J. Gastroenterol. 1994; 89: 101-5.
115. 115 Chan AOO, Chu KM, Kwok E et al. Serum soluble E-cadherin concentration is a good prognostic marker for patients with gastric cancer. Gastroenterology 1999; 116: A388.
116. 116 Levitzki A, Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science 1995; 267: 1782-8.
117. 117 Sasaki S, Tsujisaki M, Jinnohara T et al. Human tumor growth suppression by apoptosis induced with anti-ErbB-2 chimeric monoclonal antibody. Jpn. J. Cancer Res. 1998; 89: 562-70.